Oncology and Autoimmune Diseases

B2069

Indications ——SLE、ALS and other autoimmune diseases

资源 29

Research progress

Pre-clinical research

Potential Advantages

(1) Systemic lupus erythematosus (SLE) and amyotrophic lateral sclerosis (ALS), representative of autoimmune diseases and with unclear pathogenesis, are characterized by a long course of disease, involvement of all organs in the body, and high malignancy. Currently, there is a lack of effective treatments. B2069 is an innovative, fully-human bispecific antibody designed to block the two critical signaling pathways in immune response and produce a double inhibiting effect in the treatment of multiple-system, severe autoimmune diseases. It offers a totally new strong treatment regimen for patients;
(2) With critical cytokines in the immune cell pathway as its design target 1, B2609 binds to non-bingding cytokines to reduce inflammatory response in the downstream. Its design target 2 targetedly binds to pivotal factors in the complement channel’s signaling pathway to produce a blocking effect.
Next important events and time points
 
It is anticipated that preclinical pharmacodynamics, pharmacokinetics and safety evaluation studies will be initiated in the first quarter of 2022, and an IND application will be filed in the first quarter of 2023.